Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc. is a leader in the production of pharmaceutical cannabidiol and the development of innovative cannabidiol medicines for heart disease.

Recent News

  • Cardiol Therapeutics to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference

    Oakville, Ontario--(Newsfile Corp. - September 15, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular diseases, including heart failure and acute myocarditis, announces that Cardiol's President and CEO, Mr. David Elsley, will present a company overview at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference today at 12:00 PM EDT.A live webcast and replay of the presentation will be accessible...

    2020-09-15 8:07 AM ET
  • Cardiol Therapeutics Initiates Health Canada Approved Phase 1 Clinical Study of CardiolRx(TM)

    Oakville, Ontario--(Newsfile Corp. - August 26, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular diseases, including heart failure and acute myocarditis, is pleased to announce the initiation of its Health Canada approved Phase 1 clinical study of CardiolRx™. CardiolRx is an extra strength formulation of pharmaceutical cannabidiol that has been formulated to set the highest industry standard for purity, consistency,...

    2020-08-26 7:27 AM ET
  • Cardiol Therapeutics Appoints CNBC Market Analyst Steven Grasso as Business Advisor

    Oakville, Ontario--(Newsfile Corp. - June 29, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it has appointed Steven Grasso as Business Advisor to the Company.Steven Grasso began his career on the floor of the New York Stock Exchange in 1993. He joined Stuart Frankel & Co. as an...

    2020-06-29 7:27 AM ET
  • Cardiol Therapeutics Closes $17.25 Million Bought Deal Offering, Including Full Exercise of the Over-Allotment Option

    Oakville, Ontario--(Newsfile Corp. - June 4, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce the closing of its previously announced "bought deal" short form prospectus offering (the "Offering") of units of the Company ("Units") for aggregate gross proceeds of $17,250,000 which includes the full exercise of the over-allotment option."The closing of our financing today...

    2020-06-04 9:07 AM ET
  • Cardiol Therapeutics Reports 2020 AGM Results

    Oakville, Ontario--(Newsfile Corp. - June 2, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, announces results from its Annual General Meeting ("AGM") of shareholders held in Toronto, Ontario, on June 1, 2020. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular.Resolutions proposed and approved at the AGM are:The re-election of...

    2020-06-02 3:45 PM ET
  • Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 1st at 4:30 p.m. EDT

    Oakville, Ontario--(Newsfile Corp. - May 29, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it will webcast the Company's virtual Annual General Meeting of Shareholders (the "AGM") on June 1, 2020, at 4:30 p.m. EDT.Cardiol Therapeutics 2020 AGM  When:  June 1, 2020 

    2020-05-29 9:37 AM ET
  • Cardiol Therapeutics Announces Increase to Previously Announced Bought Deal Public Offering

    Oakville, Ontario--(Newsfile Corp. - May 14, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Canaccord Genuity Corp. (the "Underwriters") to increase the size of its previously announced bought deal financing. The Underwriters have agreed to purchase, on a bought...

    2020-05-14 9:43 AM ET
  • Cardiol Therapeutics Announces $11.25 Million Bought Deal Public Offering

    Oakville, Ontario--(Newsfile Corp. - May 13, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (the "Lead Underwriter") pursuant to which the Lead Underwriter has agreed, on behalf of a syndicate of underwriters (collectively, the "Underwriters"), to purchase, on a bought deal...

    2020-05-13 5:44 PM ET